We modelled the effects and costs of widespread use of SGLT2is and GLP-1 RAs in the total and secondary prevention populations with type 2 diabetes in Australia, considering only their benefits on major cardiovascular and kidney outcomes, from 2020 to 2040. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.